HUNTINGDON VALLEY, Pa., Oct. 24 /PRNewswire-FirstCall/ -- Byron D. Hewett, President and CEO, and other members of senior management will provide an Immunicon update and discuss third quarter earnings results via Webcast and conference call on Wednesday November 1, 2006, at 9:00 a.m. EST.
What: Immunicon Corporation’s Third Quarter 2006 Financial Earnings Call and Webcast When: Wednesday, November 1, 2006 at 9:00 a.m. EST How: To participate in the live call by telephone, the dial-in number for domestic U.S. listeners is (866) 713-8395 using passcode: 83450282. International callers may dial (617) 597-5309 using passcode: 83450282. In addition, a live audio webcast of the call will be available online at Immunicon’s corporate Web site at http://www.immunicon.com. Webcast participants are encouraged to log on to the site at least 15 minutes prior to the scheduled start time to register, download, and install any necessary audio software. Contact: Denise Portner, Tierney Communications, (215) 790-4395
Following the call, a webcast audio replay will be available on the Company’s web site for 30 days through Friday, November 29, 2006. In addition, a dial-in replay will be maintained for 5 days through Monday, November 6, and can be accessed by dialing (888) 286-8010 (U.S. listeners) or (617) 801-6888 (International dialers) using reservation code: 37463886.
The conference call audio will also be distributed over the Thomson/CCBN Investor Distribution Network to both institutional and individual investors. Individual investors can listen to the call through the Thomson/CCBN individual investor center at www.earnings.com or by visiting any of the investor sites in the Thomson/CCBN Individual Investor Network. Institutional investors can access the call via the Thomson/CCBN password-protected event management site, StreetEvents (www.streetevents.com).
About Immunicon Corporation
Immunicon Corporation is developing and commercializing proprietary cell- and molecular-based human diagnostic and life science research products, and is providing certain analytical services to pharmaceutical and biotechnology companies to assist them in developing new therapeutic agents, with an initial focus on cancer disease management. Immunicon has developed platform technologies to identify, count and characterize a small number of rare cells in blood, such as circulating tumor cells and circulating endothelial cells that are important in many diseases and biological processes. Immunicon’s products and underlying technology platforms also have application in cancer research and may have applications in other fields of medicine, such as cardiovascular and infectious diseases. For more information, please visit www.immunicon.com.
Forward-Looking Statements
This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are often preceded by words such as “hope,” “may,” “believe,” “anticipate,” “plan,” “expect,” “intend,” “assume,” “will” and similar expressions. Forward-looking statements contained in this press release include, among others, statements relating to the anticipated clinical utility of Immunicon’s products and other statements not of historical fact. Immunicon cautions investors not to place undue reliance on these forward- looking statements, which speak only as of the date of this press release, are based on the current expectations and intent of the management of Immunicon and involve certain factors, such as risks and uncertainties that may cause actual results to be far different from those suggested by these statements. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict, including, but not limited to, risks and uncertainties associated with: Immunicon’s dependence on Veridex, LLC, a Johnson & Johnson company, in the field of cancer cell analysis; the ability to earn license and milestone payments under Immunicon’s agreement with Veridex; Immunicon’s capital and financing needs; research and development and clinical trial expenditures; commercialization of product candidates; Immunicon’s ability to obtain licenses from third parties to commercialize products; Immunicon’s ability to manage its growth; obtaining necessary regulatory approvals; reliance on third party manufacturers and suppliers; reimbursement by third party payors to Immunicon’s customers; compliance with applicable manufacturing standards; retaining key personnel; delays in the development of new products or planned improvements to products; effectiveness of products compared to competitors’ products; protection of Immunicon’s intellectual property; conflicts with third party intellectual property; product liability lawsuits that may be brought against Immunicon; labor, contract or technical difficulties; and competitive pressures in Immunicon’s industry. These factors are discussed in more detail in Immunicon’s filings with the Securities and Exchange Commission. Except as required by law, Immunicon accepts no responsibility for updating the information contained in this press release beyond the published date, whether as a result of new information, future events or otherwise, or for modifications made to this document by Internet or wire services.
“Immunicon” and the Immunicon Corporation logo are registered trademarks of Immunicon Corporation. ALL RIGHTS RESERVED.
Contact Information: James G. Murphy SVP of Finance & Administration, CFO 215-346-8313 jmurphy@immunicon.com Investors/Media: Tierney Communications Denise Portner Vice President 215-790-4395 dportner@tierneyagency.com
Immunicon Corporation
CONTACT: James G. Murphy, SVP of Finance & Administration, CFO ofImmunicon Corporation, +1-215-346-8313 or jmurphy@immunicon.com, orInvestors/Media: Denise Portner, Vice President of Tierney Communicationsfor Immunicon Corporation, +1-215-790-4395 or dportner@tierneyagency.com
Web site: http://www.immunicon.com/
